| Literature DB >> 32336269 |
Vishwajeet Singh1, Sada Nand Dwivedi2, S V S Deo3.
Abstract
BACKGROUND: Oral cancer is the most common cancer among Indian men, and has strong tendency of metastatic spread to neck lymph node which strongly influences prognosis especially 5 year survival-rate and also guides the related managements more effectively. Therefore, a reliable and accurate means of preoperative evaluation of extent of nodal involvement becomes crucial. However, earlier researchers have preferred to address mainly its dichotomous form (involved/not-involved) instead of ordinal form while dealing with epidemiology of nodal involvement. As a matter of fact, consideration of ordinal form appropriately may increase not only the efficiency of the developed model but also accuracy in the results and related implications. Hence, to develop a model describing factors associated with ordinal form of nodal involvement was major focus of this study.Entities:
Keywords: Nodal involvement; Oral cancer; Ordinal logistic regression; Squamous cell carcinoma
Mesh:
Year: 2020 PMID: 32336269 PMCID: PMC7183690 DOI: 10.1186/s12874-020-00985-1
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.615
Distribution and association of nodal involvement with various covariates
| Variables | Freq (%) | No Nodes | 1 Node(+) | 2–4 Node(+) | > 4 Node(+) | ||
|---|---|---|---|---|---|---|---|
| Gender | Female | 212 (22.4) | 116 (54.7) | 31 (14.6) | 44 (20.8) | 21 (9.9) | |
| Male | 733 (77.6) | 453 (61.8) | 118 (16.1) | 118 (16.1) | 44 (6.0) | 0.062 | |
| Age | < 40 | 184 (19.5) | 113 (61.4) | 31 (16.8) | 29 (15.8) | 11 (6.0) | |
| (years) | 40–60 | 549 (58.1) | 322 (58.6) | 90 (16.4) | 94 (17.1) | 43 (7.8) | |
| > 60 | 212 (22.4) | 134 (63.2) | 28 (13.2) | 39 (18.4) | 11 (5.2) | 0.682 | |
| Soc-Eco | LC | 252 (26.7) | 151 (59.9) | 37 (14.7) | 45 (17.9) | 19 (7.5) | |
| Status | LMC | 499 (52.8) | 309 (61.9) | 70 (14.0) | 84 (16.8) | 36 (7.2) | |
| UMC | 174 (18.4) | 97 (55.7) | 38 (21.8) | 31 (17.8) | 8 (4.6) | ||
| UC | 20 (2.1) | 12 (60.0) | 4 (20.0) | 2 (10.0) | 2 (10.0) | 0.451 | |
| Pain | No | 521 (55.1) | 330 (63.3) | 80 (15.4) | 84 (16.1) | 27 (5.2) | |
| Yes | 424 (44.9) | 239 (56.4) | 69 (16.3) | 78 (18.4) | 38 (9.0) | 0.056 | |
| Dur. Of | < 3 | 250 (26.5) | 146 (58.4) | 43 (17.2) | 41 (16.4) | 20 (8.0) | |
| Symp. | > = 3 & < 6 | 372 (39.4) | 216 (58.1) | 60 (16.1) | 66 (17.7) | 30 (8.1) | |
| (months) | > = 6 | 323 (34.1) | 207 (64.1) | 46 (14.2) | 55 (17.0) | 15 (4.6) | 0.448 |
| Leukoplakia | No | 862 (91.2) | 513 (59.5) | 140 (16.2) | 151 (17.5) | 58 (6.7) | |
| Yes | 83 (8.8) | 56 (67.5) | 9 (10.8) | 11 (13.3) | 7 (8.4) | 0.345 | |
| Smoking | No | 592 (62.6) | 342 (57.8) | 97 (16.4) | 106 (17.9) | 47 (7.9) | |
| Yes | 353 (37.4) | 227 (64.3) | 52 (14.7) | 56 (15.9) | 18 (5.1) | 0.166 | |
| SMF | No | 904 (95.7) | 538 (59.5) | 142 (15.7) | 160 (17.7) | 64 (7.1) | |
| Yes | 41 (4.3) | 31 (75.6) | 7 (17.1) | 2 (4.9) | 1 (2.4) | 0.081 | |
| Dur. Risk | 0 | 162 (17.2) | 93 (57.4) | 24 (14.8) | 27 (16.7) | 18 (11.1) | |
| (months) | ≤60 | 92 (9.7) | 52 (56.5) | 11 (12.0) | 23 (25.0) | 6 (6.5) | |
| > 60 & ≤120 | 240 (25.4) | 136 (56.7) | 49 (20.4) | 40 (16.7) | 15 (6.3) | ||
| > 120 & ≤240 | 262 (27.7) | 167 (63.7) | 42 (16.0) | 41 (15.7) | 12 (4.6) | ||
| > 240 | 189 (20.0) | 121 (64.0) | 23 (12.2) | 31 (16.4) | 14 (7.4) | 0.117 | |
| cTumor | UIG | 386 (40.8) | 221 (57.2) | 69 (17.9) | 70 (18.1) | 26 (6.7) | |
| Growth | UPG | 539 (57.0) | 335 (62.1) | 78 (14.5) | 89 (16.5) | 37 (6.9) | |
| Other | 20 (2.2) | 13 (65.0) | 2 (10.0) | 3 (15.0) | 2 (10.0) | 0.710 | |
| c T Stage | T1 | 80 (8.5) | 51 (63.7) | 13 (16.3) | 9 (11.2) | 7 (8.8) | |
| T2 | 252 (26.7) | 145 (57.5) | 52 (20.6) | 46 (18.3) | 9 (3.6) | ||
| T3 | 99 (10.5) | 61 (61.6) | 11 (11.1) | 17 (17.2) | 10 (10.1) | ||
| T4 | 514 (54.3) | 312 (60.7) | 73 (14.2) | 90 (17.5) | 39 (7.6) | 0.102 | |
| Trismus | No | 724 (76.6) | 437 (60.4) | 107 (14.8) | 126 (17.4) | 54 (7.5) | |
| Yes | 221 (23.4) | 132 (59.7) | 42 (19.0) | 36 (16.3) | 11 (5.0) | 0.312 | |
| cSkinInv | No | 721 (76.3) | 429 (59.5) | 121 (16.8) | 125 (17.3) | 46 (6.4) | |
| Yes | 224 (23.7) | 140 (62.5) | 28 (12.5) | 37 (16.5) | 19 (8.5) | 0.333 | |
| OCF | No | 916 (96.9) | 549 (59.9) | 145 (15.8) | 159 (17.4) | 63 (6.9) | |
| Yes | 29 (3.1) | 20 (69.0) | 4 (13.8) | 3 (10.3) | 2 (6.9) | 0.738 | |
| cBoneInv | No | 694 (73.4) | 426 (61.4) | 112 (16.1) | 111 (16.0) | 45 (6.5) | |
| Yes | 251 (26.6) | 143 (57.0) | 37 (14.7) | 51 (20.3) | 20 (8.0) | 0.331 | |
| cNeck Node | No | 233 (24.7) | 171 (73.4) | 33 (14.2) | 23 (9.9) | 6 (2.6) | |
| Yes | 712 (75.3) | 398 (55.9) | 116 (16.3) | 139 (19.5) | 59 (8.3) | < 0.001 | |
| Oral Site | BM | 272 (28.7) | 175 (64.3) | 42 (15.4) | 41 (15.1) | 14 (5.2) | |
| Tongue | 200 (21.3) | 110 (55.0) | 33 (16.5) | 38 (19.0) | 19 (9.5) | ||
| Alvelobuccal | 177 (18.7) | 100 (56.5) | 30 (17.0) | 31 (17.5) | 16 (9.0) | ||
| Alveolus | 104 (11.0) | 59 (56.7) | 20 (19.2) | 18 (17.3) | 7 (6.7) | ||
| CA & FOM | 90 (9.5) | 62 (68.9) | 9 (10.0) | 14 (15.6) | 5 (5.6) | ||
| RMT | 54 (5.7) | 37 (68.5) | 7 (13.0) | 8 (14.8) | 2 (3.7) | ||
| Lip | 48 (5.1) | 26 (54.2) | 8 (16.7) | 12 (25.0) | 2 (4.2) | 0.551 | |
| Deg. of Diff. | WD | 658 (69.6) | 410 (62.3) | 102 (15.5) | 104 (15.8) | 42 (6.4) | |
| Others | 287 (30.4) | 159 (55.4) | 47 (16.4) | 58 (20.2) | 23 (8.0) | 0.194 | |
| Tumor Size | <=2 | 256 (27.1) | 165 (64.4) | 39 (15.2) | 41 (16.0) | 11 (4.3) | |
| (cm) | > 2 and < =4 | 466 (49.3) | 270 (57.9) | 86 (18.5) | 80 (17.2) | 30 (6.4) | |
| > 4 | 223 (23.6) | 134 (60.1) | 24 (10.8) | 41 (18.4) | 24 (10.8) | 0.022 | |
| Total | 945 (100) | 569 (60.2) | 149 (15.8) | 162 (17.1) | 65 (6.9) |
LC Lower class, LMC Lower middle class, UC Upper class, UMC Upper middle class, UIG Ulceroinfiltrative, UPG, ulceroproliferative, WD Well Differentiated; Deg. of Diff. Degree of differentiation, cSkin Inv clinical skin involvement, cBone Inv clinical bone involvement, SMF sub mucous fibrosis.
Factors associated with cervical lymph node involvement using proportional odds model
| Variables | UOR(95%CI) | AOR(95%CI)* | |
|---|---|---|---|
| Pain | No | 1 | 1 |
| Yes | 1.37 (1.07 to 1.77) | 1.37(1.05 to 1.78) | |
| SMF | No | 1 | 1 |
| Yes | 0.44 (0.22 to 0.90) | 0.43 (0.21 to 0.90) | |
| cNeck Node | No | 1 | 1 |
| Yes | 2.28 (1.66 to 3.14) | 2.42 (1.73 to 3.39) | |
| Oral Site | BM | 1 | 1 |
| Tongue | 1.53 (1.07 to 2.18) | 1.83 (1.25 to 2.68) | |
| Alvelobuccal | 1.42 (0.98 to 2.06) | 1.19 (0.80 to 1.75) | |
| Alveolus | 1.34 (0.86 to 2.07) | 1.13 (0.72 to 1.80) | |
| CA & FOM | 0.87 (0.52 to 1.43) | 0.65 (0.38 to 1.11) | |
| RMT | 0.84 (0.46 to 1.55) | 0.78 (0.41 to 1.46) | |
| Lip | 1.49 (0.83 to 2.67) | 1.72 (0.94 to 3.13) | |
| Deg. of Diff. | WD | 1 | 1 |
| Others | 1.34 (1.02 to 1.75) | 1.41 (1.07 to 1.86) | |
| Tumor Size | <=2 | 1 | 1 |
| (cm) | > 2 and < =4 | 1.29 (0.95 to 1.75) | 1.18 (0.86 to 1.63) |
| > 4 | 1.36 (0.95 to 1.96) | 1.18 (0.80 to 1.74) |
UOR Unadjusted odds ratio, AOR Adjusted odds ratio.
*Adjusted in relation to smoking and clinical bone involvement
Factors associated with cervical lymph node involvement using partial proportional odds model
| Variables | UOR(95%CI) | AOR(95%CI)* | |
|---|---|---|---|
| Pain | No | 1 | 1 |
| Yes | 1.37 (1.07 to 1.77) | 1.39(1.06 to 1.81) | |
| SMF | No | 1 | 1 |
| Yes | 0.44 (0.22 to 0.90) | 0.43 (0.21 to 0.90) | |
| cNeck Node | No | 1 | 1 |
| Yes | 2.28 (1.66 to 3.14) | 2.44 (1.75 to 3.42) | |
| Oral Site | BM | 1 | 1 |
| Tongue | 1.53 (1.07 to 2.18) | 1.83 (1.25 to 2.69) | |
| Alvelobuccal | 1.42 (0.98 to 2.06) | 1.19 (0.80 to 1.76) | |
| Alveolus | 1.34 (0.86 to 2.07) | 1.15 (0.73 to 1.83) | |
| CA & FOM | 0.87 (0.52 to 1.43) | 0.65 (0.38 to 1.12) | |
| RMT | 0.84 (0.46 to 1.55) | 0.77 (0.40 to 1.45) | |
| Lip | 1.49 (0.83 to 2.67) | 1.72 (0.95 to 3.13) | |
| Deg. of Diff. | WD | 1 | 1 |
| Others | 1.34 (1.02 to 1.75) | 1.42 (1.07 to 1.87) | |
| Tumor Size | <=2 | 1 | 1 |
| (cm) | > 2 and < =4 | 1.30 (0.96 to 1.77) | 1.19 (0.87 to 1.64) |
| > 4 | 1.20 (0.83 to 1.73) | 1.01 (0.68 to 1.50) | |
| Cut2 | 1.69 (1.14 to 2.51) | 1.47 (0.97 to 2.24) | |
| Cut3 | 2.39 (1.35 to 4.22) | 2.12 (1.18 to 3.79) |
UOR Unadjusted odds ratio, AOR Adjusted odds ratio. Cut2, category 4,3 vs. 2,1; Cut2, category 4 vs. 3, 2,1.; *Adjusted in relation to smoking and clinical bone involvement.
Comparison of the developed models
| Model | LR | AIC | BIC |
|---|---|---|---|
| POM | − 988.79 | 2011.57 | 2094.04 |
| PPOM | − 983.18 | 2004.37 | 2096.54 |